1992
DOI: 10.1007/bf01629431
|View full text |Cite
|
Sign up to set email alerts
|

Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells

Abstract: Blood eosinophilia in tumor patients treated with interleukin-2 (IL-2) is well known and is regarded as evidence of toxicity or as a side-effect [Lotze et al. (1986) Arch Surg 121:1373-1379; West et al. (1987) N Engl J Med 316:898-905]. We recently described a new local IL-2 approach to therapy for advanced bladder carcinoma that allows, for the first time, high-dose continuous administration of natural interleukin-2 (nIL-2) at the tumor site without side-effects [Huland and Huland (1989) Cancer Res 49:5469-54… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
41
0

Year Published

1995
1995
2020
2020

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 61 publications
(42 citation statements)
references
References 11 publications
1
41
0
Order By: Relevance
“…Whether the raised serum level of the granule proteins in combination with significantly raised blood eosinophil counts is a consequence of the activation of the circulating pool of eosinophils or is a reflection of the release of these proteins at the site of the tumour cannot be judged from this study. However, eosinophil infiltration and degranulation in tumours have been seen (Huland & Huland, 1992) and some leakage of granule proteins from such areas to the blood is possible. Significantly increased levels of EPX in serum and a tendency in the same direction was observed after IL2/IFN-a treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Whether the raised serum level of the granule proteins in combination with significantly raised blood eosinophil counts is a consequence of the activation of the circulating pool of eosinophils or is a reflection of the release of these proteins at the site of the tumour cannot be judged from this study. However, eosinophil infiltration and degranulation in tumours have been seen (Huland & Huland, 1992) and some leakage of granule proteins from such areas to the blood is possible. Significantly increased levels of EPX in serum and a tendency in the same direction was observed after IL2/IFN-a treatment.…”
Section: Discussionmentioning
confidence: 99%
“…The antitumor effect of systemic IL-2 therapy is also correlated with degranulation of eosinophils within the tumors (47,48); this degranulation may occur via antibody-dependent mechanisms (61). In addition, IL-25 has been shown to have antitumor activity in vivo; IL-25 treatment leads to eosinophilia, which is correlated with tumor suppression (62).…”
Section: Cytokinesmentioning
confidence: 99%
“…Reports of immunotherapeutic approaches and recent in vitro and in vivo studies, however, suggest that eosinophils are involved in tumoricidal activity. [112][113][114] Degranulated eosinophils have been detected in tumors following systemic administration of IL-2, suggesting that they may play an effective role in the anti-tumor response either by inducing direct tumor cell lysis through release of their toxic granules, by antibody-dependent mechanisms of eosinophil activation, or by their immuno-regulation of the tumor microenvironment. 112 However, the link between immunotherapeutic anti-tumor efficacy and eosinophilia is mainly based on correlation analyses, and no conclusions can be drawn regarding the actual mechanisms of action of eosinophils in the modulation of tumor growth.…”
Section: Mast Cellsmentioning
confidence: 99%